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Abstract
Angiogenesis is associated with follicular development and is regulated independently within each
follicle potentially making the functioning of its vasculature critically important in determining its
fate. This review examines the various ways in which follicular angiogenesis may be monitored,
describes the follicular localisation and changes in pro- and anti-angiogenic factors that may regulate
the process and how antagonists may be used to elucidate their physiological role in vivo. Thus,
inhibition of vascular endothelial growth factor (VEGF), VEGF receptor-2, vascular endothelial cell
cadherin or interference with the angiopoietin system can inhibit follicular development or prevent
ovulation.
Introduction
Aside from wound healing and certain pathological proc-
esses, including neoplasia, the vascular system in the adult
is generally quiescent. An exception takes place in the ova-
ries where there is intense angiogenesis and increased per-
meability of blood vessels during follicular development,
ovulation and subsequent formation of the corpus
luteum. Furthermore, angiogenesis is regulated independ-
ently within each individual follicle and depending on the
extent of the vascular plexus and permeability of vessels,
the supply of large molecular weight tropic factors, precur-
sors and lipids can be controlled. This indicates the follic-
ular vasculature could be intimately involved in the
processes of follicular selection, dominance and atresia.
It is likely that some types of infertility are associated with
disturbance of follicular angiogenesis resulting in inade-
quate development. In polycystic ovarian syndrome there
is excessive angiogenesis while ovarian hyperstimulation
syndrome (OHHS) is associated with an increase in capil-
lary permeability. Thus, an understanding of the mecha-
nisms of follicular angiogenesis and its regulation may
lead to therapies for controlling inappropriate follicle
development secondary to decreased or enhanced angio-
genesis. The identification of putative angiogenic factors
in the ovary and development of specific agonists or
antagonists of angiogenic molecules, together with their
application in animal models, presents novel opportuni-
ties to validate their physiological role in vivo. This review
outlines the methods that are being used to study changes
in the follicular vasculature, address the work on some of
the angiogenic factors which have been studied in the
ovary and seem of particular interest at this time, and
examines the effects of manipulation of these factors on
follicular angiogenesis and development in vivo.
Monitoring of follicular angiogenesis
While primordial and primary follicles receive nutrients
and oxygen by passive diffusion from stromal blood ves-
sels, follicular growth is associated with the development
of an individual capillary network and continued angio-
genesis to nourish the rapidly expanding follicle. The vas-
cular sheath that develops around each follicle is confined
to the thecal layer by the presence of the membrana pro-
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pria until the breakdown of the basement membrane at
ovulation. Some of the methods employed to monitor the
progress of the follicular vasculature are outlined below.
Measurement of ovarian blood flow can be achieved non-
invasively by color and pulsed Doppler ultrasonography
in species with sufficiently large and accessible ovaries
such as humans, cattle and horses. This demonstrates
increased flow to the ovary containing the dominant fol-
licle. In addition, there is increased peak flow velocity
with increasing follicular size and high vascularity and
flow velocity of the dominant follicle before ovulation
[1]. In mares this technique has been used to detect reduc-
tions in blood flow area in follicles under conditions
where LH stimulation is deficient [2]. New opportunities
will arise from advances in technology of high resolution
imaging systems for research on small animals, together
with the use of contrast agents to enable the imaging of
the ovarian vasculature more effectively on a wider scale.
Dynamics of ovarian blood supply to preovulatory folli-
cles has been investigated by injection of radioactive
microspheres into the ovarian artery and shows that the
elevation in follicular blood supply associated with the
preovulatory LH surge is followed by a fall in blood sup-
ply as the time of follicular rupture approaches [3]. The
spatial distribution of microvessels in the follicular thecal
layer may be visualised by scanning electron microscopy
of ovarian corrosion casts. This allows angiogenesis to be
identified and quantified in individual follicles by identi-
fying sites of budding, sprouting and splitting of capillar-
ies from pre-existing blood vessels. In addition, vascular
degeneration can be determined by quantifying numbers
of incompletely filled or thinned capillaries [4]. In cattle,
angiogenesis was observed mainly in the apical part of the
inner capillary layer of medium follicles and the middle
or basal part of the capillary layer of healthy dominant
follicles. In atretic follicles large avascular areas were
observed in the inner thecal layer associated with apopto-
sis.
The most widely employed approach to study changes in
angiogenesis during follicular development is to use ovar-
ian sections in which endothelial cells are stained with a
specific marker. Changes in endothelial cell area can then
be quantified using image analysis. The most commonly
used marker is platelet endothelial cell adhesion molecule
(PECAM/CD31), a membrane protein that mediates cell-
cell adhesion and is reliably detected in endothelial cells
in the follicles of, e.g., the mouse [5,6], rat [7] marmoset
[8,9] and macaque [10]. Although CD31 may be used to
localise endothelium in the human ovary, CD34, a trans-
membrane glycoprotein, has proven to be the marker of
choice [11,12]. Unfortunately, CD34 antibodies seem to
cross-react less in other species. Where neither of these
markers are detectable with available antibodies, antibod-
ies to factor VIII/von Willebrand factor may be used suc-
cessfully to localise the follicular endothelium, e.g. in the
mare [13], pig [14] and cow [15]. Recently, another
potential marker, vascular endothelial cell cadherin (VE-
cadherin), has been localised in mouse follicles [5]. Alter-
natively, blood vessels may be localised in all species by
attachment of carbohydrate lectins that have been bioti-
nylated or fluorescein-labelled as demonstrated e.g., for
bovine [15] buffalo [16] and sheep [17] ovaries. In small
animals, blood vessels can also potentially be visualised
after infusion of lectin [6]. These studies show that large
vessels are predominantly located in the outer thecal
layer, while smaller vessels are observed in the vicinity of
the inner layer close to the lamina basalis. Intravenous
injection of labelled gonadotropin in macaques showed
highest accumulation in the follicle destined to ovulate
[18] suggesting pre-ovulatory follicles had developed the
highest blood supply. In most species, vascular area is
highest in the dominant follicles [e.g. 9], although in a
study of the human ovary, no significant difference in vas-
cular density between dominant and non-dominant folli-
cles were detected [11]. This may reflect species
differences in the extent of development of non-dominant
follicles. Follicular atresia is associated with inadequate
development and/or regression of the thecal vasculature
in most species studied [e.g. 8, 9], although this was not
confirmed for the human ovary, and it has been suggested
that this is related to the longer time taken for the atretic
process [11].
Proliferating endothelial cells may be visualised and
quantified by dual immunostaining using markers of
endothelial cell proteins to localize to the cytoplasm
together with proliferation markers localised to the
nucleus. For example, nuclear incorporation of exogenous
bromodeoxyuridine (BrdU) [8,9] or localisation of Ki67
[10,13] has been widely used. Significant cell prolifera-
tion is first seen in the theca of early secondary follicles,
when endothelial cell specific staining is still absent, dem-
onstrating that the establishment of the theca compart-
ment precedes angiogenesis [8]. As the follicle continues
to develop, endothelial cells are recruited to the thecal
layer from the blood vessels in the adjacent ovarian
stroma. In the late secondary and tertiary phases of follic-
ular development, 25–30 % of proliferating cells in the
inner thecal layer are of endothelial cell origin [8]. The
appearance of endothelial cells in secondary follicles with
more than 4 granulosa cell layers (late secondary, end of
pre-antral stage) [8] coincides with a marked increase in
proliferation within the thecal layer. Angiogenesis, calcu-
lated by proportion of proliferating endothelial cells,
gradually increases in the developing follicle, reaching
maximal levels at the late pre-antral/early antral stage.
Endothelial cell proliferation is maintained in healthy ter-Reproductive Biology and Endocrinology 2006, 4:18 http://www.rbej.com/content/4/1/18
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tiary follicles to support the ongoing expansion of the the-
cal vasculature.
In general, the above observations support the idea that
vascular development plays a crucial role in the latter
stages of follicular growth, and the selection of the ovula-
tory follicle. In particular, they suggest that efficient elab-
oration of competent blood vessels and maintenance of
vascular permeability is necessary to maintain adequate
delivery of gonadotropins, nutrients and oxygen necessary
to sustain rapid follicular growth. A disruption of the fol-
licular vasculature during the early stages of atresia would
be a logical mechanism leading to a reduced supply of
tropic factors and nutrients to the follicle, although such a
cause and effect has yet to be established.
Molecular regulation of follicular angiogenesis
The localisation and regulation of a large number of estab-
lished and putative angiogenic factors and their receptors
in the ovary has been described using a combination of
northern blot, RT-PCR and in situ hybridization to meas-
ure mRNA and western blot and immunocytochemistry to
investigate protein. The definition of changes in their tem-
poral and spatial expression patterns in relation to specific
stages of follicular development have implied a role for a
large number of factors which suggests the process
involves a series of complex interactions between numer-
ous regulatory molecules. Although angiogenesis is con-
fined to the thecal layer and the receptors for angiogenic
factors are found predominantly on the ovarian vascular
endothelium and associated cells, many of the factors that
regulate the process are predominantly synthesised in the
granulosa.
Studies in which angiogenic factors, or specific antago-
nists, are administered over selected periods of follicular
growth must be conducted in order to confirm the postu-
lated physiological roles of these factors in the regulation
of follicular angiogenesis and function. Most studies have
employed systemic administration, but the ability to
inject factors directly into the ovarian follicle has been
also employed [e.g. 19]. Examples of some of the factors
that are currently being investigated in the ovary are
described below.
Vascular endothelial growth factor
Predominant among the candidates is the pro-angiogenic
vascular endothelial growth factor (VEGF) family [20].
The most significant of the VEGF is VEGF-A (hereafter
VEGF) that is produced in a number of isoforms, VEGF
165 being the most prominent in the ovary [21]. Other
members are -B, -C, and D together with placental growth
factor (PLGF). VEGF is a potent and specific stimulator of
vascular endothelial cell proliferation acting through two
tyrosine kinase receptors, VEGFR-1 (formerly known as
Flt-1) and VEGFR-2 (KDR). In addition, VEGF has potent
permeability actions and may act as a survival factor for
immature vessels.
With respect to the localisation of VEGF mRNA and pro-
tein during the course of follicular development in the
ovary, although there may be some species differences, a
general pattern is apparent [9,12]. Typically as in the mar-
moset, VEGF mRNA is absent from primordial, primary
and early secondary follicles and is first detected in the
theca and granulosa cell layers of secondary follicles when
the follicle develops its own vascular network [9]. Interest-
ingly, this stage of development is largely independent of
gonadotropin stimulation and treatment with GnRH
antagonist failed to affect VEGF mRNA expression as
determined by semi-quantitative in situ hybridization [9].
A further increase in VEGF mRNA expression is observed
within the granulosa of follicles in the late secondary and
tertiary stages, while expression in the theca is lower and
remains fairly constant. This is the stage of follicular
development that is becoming dependent on gonadotro-
pin stimulation and VEGF mRNA is stimulated by gona-
dotropins in vitro [22] and decreased after treatment with
GnRH antagonist in vivo [9].
Surprisingly, in follicles that appear very close to ovula-
tion, VEGF synthesis declined in the granulosa cells and
exhibited a punctate expression in cells in the thecal layer
at the border with the granulosa [8]. The distribution of
VEGF receptors in endothelial cells of follicles has been
demonstrated by in situ hybridization [23] and immuno-
cytochemistry [12].
Specific inhibition of the VEGF pathway in vivo, with
resultant effects on follicular function, has been achieved
using neutralising antibodies against VEGF itself [24],
antibodies against VEGFR-2 [25], a VEGFR tyrosine kinase
inhibitor [26], the soluble VEGF receptor, sFlt [27,28] and
receptor-based antagonists, the VEGF Traps [7,23].
VEGF Trap R1R2 comprises Ig domain 2 of VEGF-R1 and
Ig domain 3 of VEGF-R2, fused with human Fc. It blocks
all isoforms of VEGF A, VEGF B and PlGF but does not
inhibit VEGF C and D. Marmosets treated with VEGF Trap
from the beginning of the 10-day follicular phase had
healthy pre-antral and small antral follicles in their ova-
ries, but large antral follicles, characteristically present in
ovaries of late follicular phase control marmosets, were
absent (Figure 1). Morphometric analysis of the theca of
late secondary and tertiary follicles revealed a marked
decrease in cell proliferation and reduction in endothelial
cell area in the treated animals (Figure 2). Cellular prolif-
eration in the theca was reduced by 80% relative to con-
trols, indicating that the proliferation of non-endothelial
cells was also inhibited [23]. Antral follicular develop-Reproductive Biology and Endocrinology 2006, 4:18 http://www.rbej.com/content/4/1/18
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ment was further compromised as indicated by a decrease
in granulosa cell proliferation, reduced average diameter
of early antral follicles as well as the absence of large terti-
ary follicles. Expression of VEGFR-1 and VEGFR-2 mRNA
in the endothelial cells of the residual thecal vasculature
was markedly reduced [23]. As the expression of VEGF
receptors is positively regulated by exposure to ligand, this
observation provides evidence that VEGF Trap effectively
blocked the stimulation of ovarian endothelial cells by
endogenous VEGF.
Taken together, the above observations indicate that the
inhibition of follicular maturation by blocking VEGF is
secondary to attenuation of follicular vascular density
and/or permeability, which in turn reduces the availabil-
ity of growth factors, hormones, lipoproteins, nutrients
and oxygen to the growing follicles. These data serve to
highlight the absolute requirement for VEGF during follic-
ular angiogenesis and development.
To evaluate the importance of VEGF within the peri-ovu-
latory follicle in the rhesus monkey, the approach of direct
injection of VEGF antagonist (soluble receptor) into the
pre-ovulatory follicle has been investigated [29]. Half the
animals failed to ovulate but exhibited luteinized unrup-
tured follicles while those which did ovulate had sup-
pressed progesterone secretion with a luteal phase of
normal duration.
It is still not established whether the permeability-enhanc-
ing actions of VEGF are involved in gonadotropin access
to the dominant follicle [18], the development of follicu-
lar fluid or the final process of ovulation [30]. Studies to
test the hypothesis that expansion of the selected follicle
was dependent upon VEGF-mediated permeability exam-
ined the effects of treatment of marmosets with VEGF Trap
at the mid-follicular phase, the period of follicle selection
[31]. However, examination of the most mature follicles 5
days later at the ovulatory period in controls, showed that
while angiogenesis had been inhibited, the follicles had
undergone expansion suggesting that other mechanisms
could compensate for the inhibition of VEGF, or that it is
not the primary mediator of follicle expansion.
The effects of inhibition of VEGF at the early, mid- or late
follicular phase on pituitary-ovarian hormone profiles in
the blood have been described in macaques. When an
antibody to VEGFR-2 was administered starting during
the early follicular phase, marked changes in pituitary-
ovarian function were observed [25]. The follicular phase
rise in estradiol was delayed and inhibin B secretion was
notably suppressed. This was accompanied by a rapid rise
in serum LH and FSH secretion. These results demonstrate
the crucial role specifically of VEGFR-2 in follicular devel-
opment.
Studies with VEGF Trap in the stump-tailed macaque eval-
uated the hormonal response to a single injection of
either 4, 1 or 0.25 mg/kg, i.v. administered during the
mid-follicular phase, when the ovulatory follicle is being
selected [32]. The VEGF Trap produced a consistent, rapid
and prolonged reduction in plasma estradiol and inhibin
B levels at all doses, followed by a marked and sustained
increase in LH and FSH (e.g., Figure 3). Ovulation took
place 7 days after control injections, but was delayed in a
dose dependent manner by VEGF Trap. After decline in
serum levels of VEGF Trap, the normalization of gonado-
tropin levels was preceded by an increase in circulating
inhibin B and estradiol, and normal post-treatment
cycles. These results indicate that inhibition of VEGF at the
Effects of treatment of marmosets with VEGF Trap for 10  days on thecal and granulosa cell proliferation (BrdU incor- poration) in late secondary follicles Figure 2
Effects of treatment of marmosets with VEGF Trap for 10 
days on thecal and granulosa cell proliferation (BrdU incor-
poration) in late secondary follicles. Note the high frequency 
of cell proliferation (arrows) in the thecal layer from control 
ovary (left panel) with much reduced frequency in the ovary 
from the treated animal (right panel). This indicates a sup-
pression of endothelial cell and thecal cell proliferation. At 
this stage of development, there is no effect upon granulosa 
cell proliferation. Adapted from [23].
Effect of treatment of marmosets with VEGF Trap on follicu- lar development Figure 1
Effect of treatment of marmosets with VEGF Trap on follicu-
lar development. Haematoxylin and eosin-stained sections of 
ovaries of animals treated throughout the 10-day follicular 
phase with vehicle or VEGF Trap. Note the presence of two 
healthy dominant follicles in the control ovary, while there is 
a suppression in follicular development after VEGF Trap. 
Adapted from [23].Reproductive Biology and Endocrinology 2006, 4:18 http://www.rbej.com/content/4/1/18
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mid-follicular phase caused atresia of the most developed
follicles followed by a dose-dependent period of ovarian
quiescence leading to a characteristic follicular phase
reflecting the recruitment of a new wave of antral follicles
and maturation of a dominant follicle.
When VEGF Trap was administered in the late follicular
phase, the anticipated pre-ovulatory rise in estradiol was
blocked and although this was followed by a rapid and
sustained rise in LH and FSH, there was an absence of pro-
gesterone rises which occurred in controls a few days after
injection of control protein [32]. Subsequent ovulation
was delayed until 32 days after VEGF Trap administration.
This suggests that ovulation of the dominant follicle was
prevented and a new cohort of follicles were required to
be recruited. Administration of an antibody to VEGF dur-
ing the late follicular phase in the rhesus monkey [24]
interrupted the expected late follicular phase rise in estra-
diol and the follicular phase was extended by a week. This
suggested that VEGF inhibition interfered with the latter
sages of follicular maturation, but that the follicle
remained in a suspended state and could recover from
short-term deprivation of VEGF. The more pronounced
effects of VEGF Trap at this time may reflect higher dose or
potency than the antibody.
All the studies in which VEGF has been inhibited in
macaques have resulted in hypersecretion of LH and FSH
without apparent stimulation of follicular development.
This phenomenon has been studied directly in the mouse.
Exogenous gonadotropin administered to hypohysect-
omized animals stimulated follicle development in con-
trols, but had no effect when VEGF was inhibited using a
VEGFR-2-blocking antibody [7]. This supports the idea
that VEGF inhibition prevents access of the gonadotropins
to the follicles.
It may be that administration of angiogenic factors would
be of benefit in cases of ovarian dysfunction characterized
by impairments in follicular development and ovulation.
Whether administration of VEGF itself might be beneficial
in situations where follicular angiogenesis is inadequate is
now being addressed. Injection of VEGF gene fragments
into the ovarian medulla in pre-pubertal gilts increased
VEGF concentration in follicular fluid, follicular vascular
density, and the number of pre-ovulatory follicles when
given together with gonadotrophin [33]. Treatment of rats
with VEGF directly into the ovarian bursa stimulated pre-
antral follicle growth [34], suggesting a role in regulating
growth of early follicles. Intra follicular injection of VEGF
in the mare resulted in alteration of levels of other factors
in follicular fluid but did not increase follicular diameter
[19]. Presumably, intra follicular injection of angiogenic
molecules will cause them to cross the basement mem-
brane as it is generally acknowledged that the expression
of angiogenic factors produced by granulosa and theca
cells, acting via endothelial cell receptors, is the principal
mechanism by which pro-angiogenic factors promote fol-
licular growth. However, in vitro studies suggest ang-
iogenic factors may also act on granulosa or thecal cells
directly, in an autocrine or paracrine manner and VEGF
receptors have been reported in bovine granulosa cells,
suggesting VEGF also has a survival role in non-vascular
cells [35].
Angiopoietins
While VEGF is the prime initiator of angiogenesis, the for-
mation and differentiation of a structurally and function-
ally mature vascular network probably requires the co-
ordinated action of multiple factors. These include angi-
opoietin-1 and -2 (Ang-1 and Ang-2), which act via the
tyrosine kinase receptor, Tie-2 [36]. Follicular blood ves-
sels are unusual because they grow and mature quickly
during follicular maturation and then regress during
atresia. By the nature of their action in other systems, the
angiopoietins are of particular interest in this context,
because they function to influence the stabilisation of
newly formed vasculature, as well as the destabilisation of
existing vascular networks. Specifically, Ang-1 activation
of Tie-2 enhances the maturation and stability of newly
formed blood vessels. Ang-2 also binds to Tie-2, but can
act as an endogenous antagonist, blocking Ang-1 medi-
ated receptor phosphorylation. In the presence of VEGF,
increased autocrine expression of Ang-2 by the vascular
endothelium is associated with angiogenesis, while in the
absence of VEGF or other pro-angiogenic factors, its
expression is associated with degenerative changes in the
vasculature [36]. In situ hybridization studies on rat ova-
ries showed that Ang-2 mRNA is absent from preantral
follicles and did not become detectable until the pre-ovu-
latory stage, where its expression is associated with the
thecal blood vessels. Ang-1 is expressed in the thecal layer
uniformly during follicular development. A dramatic up
regulation of Ang-2 mRNA in the granulosa cells of atretic
follicles in association with reduced expression of VEGF
was observed [36]. Surprisingly, there are few subsequent
reports of in situ hybridization studies in the ovary. In the
marmoset, Ang-1 mRNA was detected in the theca of ter-
tiary follicles, but at a very low level while Ang-2 mRNA
was not detected in follicles, but was present in a subset of
stromal vessels [8]. In contrast to the rat, high expression
of Ang-2 is not apparent in atretic follicles in the marmo-
set ovary so that further work is required to ascertain
whether species differences exist. In bovine follicles at dif-
ferent stages of maturation in which mRNA was extracted
from the thecal and granulosa cell layers and subjected to
semi-quantitative PCR, expression for both factors was
highest in the thecal layer, while the Tie2 receptor was
present only in the thecal layer [37]. Changes in mRNA
were not marked, but tended to support the idea thatReproductive Biology and Endocrinology 2006, 4:18 http://www.rbej.com/content/4/1/18
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changes Ang-1:Ang-2 ratios in follicles were associated
with development and atresia. There do not appear to be
reports of immunocytochemical localisation of angiopoi-
etins in follicles, although Tie-2 has been described on fol-
licular endothelium [8].
Long-awaited direct evidence for a role the angiopoietins
in the ovary comes from observations in the rhesus mon-
key where local injection of Ang-2 into the pre-ovulatory
follicle blocked ovulation [38] while the same dose of
Ang-1 was without effect. It is proposed that the Ang-2
inhibited the action of Ang-1 at the level of their common
receptor and that the correct balance between these factors
is essential in maintaining the integrity of the pre-ovula-
tory follicle [38]. However, it is not known whether this
was a specific angiolytic effect, the result disruption of tis-
sue remodelling or if the Ang-2 affected the hormone-pro-
ducing cells directly. It will be of great interest to
investigate further the mechanisms involved in this action
and the effects of manipulation of the angiopoietins at
earlier stages of follicular growth.
Endocrine gland VEGF
If expression of VEGF is first detected after the initial
recruitment of a vascular network to an individual follicle,
it is likely that other pro-and anti-angiogenic factors have
a crucial role in regulating the onset of follicular angio-
genesis. Endocrine gland VEGF (EG-VEGF), also known as
prokineticin-1, is a promising angiogenic factor that is
expressed at earlier stages of follicular development. EG-
VEGF was identified from the human ovary and proposed
to function as a specific angiogenic regulator in steroidog-
enic tissues [39]. EG-VEGF is structurally unrelated to
VEGF and acts via G protein-coupled receptors. EG-VEGF
mRNA has been shown to be expressed in the follicles of
cattle and women [40,41]. In situ hybridization of human
ovaries shows the mRNA in granulosa cells of primordial
and primary follicles, while in antral follicles expression is
highest in the theca, and declines in the granulosa [41].
Since EG-VEGF and VEGF appear to exert similar and
additive effects in vitro, but are differentially regulated and
expressed in broadly complementary patterns in the ovary
[39], it has been suggested that they may also cooperate in
vivo to promote angiogenesis and the induction of the
fenestrated vascular phenotype [39]. There appear to be
major species differences in the physiology of EG-VEGF as
in mice it is not present in the ovary, yet is found in the
liver and kidney [42]. With respect to elucidation of the
physiological role of EG-VEGF, inhibitors of are currently
under development and these may be used to investigate
the role of EG-VEGF in early follicular development. Since
the latter stages of follicular angiogenesis are VEGF-
dependent while follicles at early stages of development
do not appear to be adversely affected by VEGF-inhibition
Serum concentrations of estradiol, progesterone, LH and  FSH after treatment with vehicle (arrow, open circles) or 0 Figure 3
Serum concentrations of estradiol, progesterone, LH and 
FSH after treatment with vehicle (arrow, open circles) or 
0.25 mg/kg VEGF Trap (arrow, closed circles) in the mid-fol-
licular phase in the macaque. Note the timely rise in estra-
diol, followed by the preovulatory LH/FSH surge and 
sustained rise in progesterone in controls. VEGF Trap treat-
ment results in a suppression in estradiol and an elevation in 
LH and FSH but absence of the progesterone rise in the 
treatment cycle. The progesterone rise indicating ovulation 
post-treatment took place at 24 days, suggesting recruitment 
of new follicles was required. Adapted from [32].Reproductive Biology and Endocrinology 2006, 4:18 http://www.rbej.com/content/4/1/18
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[23] it will be of particular interest to determine whether
EG-VEGF has a predominant role at this time.
Cell adhesion molecules
Although the regulation of follicular vascular permeabil-
ity has long been supposed to have a major impact on the
access of hormones and precursors, there currently exists
a dearth of information on its molecular regulation in the
ovary and the endocrine and paracrine control of the
process is just beginning to be addressed [43]. Molecules
that are likely have a role in this process, which in turn
may be regulated by VEGF amongst other factors, are
those involved in cell-cell adhesion, adherens molecules
tight junction proteins, occludins and claudins [43,44].
Endothelial cells express cell type specific trans-mem-
brane adhesion proteins such as VE-cadherin at ahherens
junctions and claudin-5 at tight junctions [44]. It has been
postulated that in the normal ovary VEGF action may
involve disruption of endothelial cell tight junction pro-
tein complex formation leading to endothelial cell fenes-
trations. It has been suggested that the hyperstimulation
of this process by excessive VEGF and other factors is an
integral part of the process of OHHS [45].
A critical role for VE-cadherin in follicular angiogenesis in
vivo has been demonstrated in the hypophysectomized
mouse. VE-cadherin was inhibited by a neutralising anti-
body that suppressed gonadotropin-induced follicular
angiogenesis and development [5].
Natriuretic peptides
Natriuretic peptides are a family of small proteins that
modulate salt and water balance as well as vascular tone
[46]. It has been proposed that atrial natriuretic peptide
acts as an anti-permeability factor by inhibiting the signal-
ling functions of VEGF by preserving endothelial cell tight
junction morphology [46]. Recently, atrial natriuretic
peptide, which has been detected in the ovary, was found
to reduce follicular growth when administered intraperi-
toneally to mice [47] although the question of effects on
angiogenesis or ovarian vascular permeability was not
addressed.
Connective tissue growth factor (CTGF)
Connective tissue growth factor (CTGF) is a cysteine-rich
secretory protein which is a member of the cysteine-rich
61/nephroblastoma-overexpressed family of genes [48]. It
has been implicated as a paracrine regulator of cell prolif-
eration, in extra cellular matrix remodelling and is gener-
ally pro-angiogenic, although in some systems it has been
shown to inhibit VEGF-induced angiogenesis. CTGF
mRNA is expressed in the theca and granulosa of the por-
cine [14] and rodent [49] ovary. Absent from small prean-
tral follicles, CTGF expression is highest in the granulosa
of mid-antral stage follicles but declines in pre-ovulatory
follicles, being down-regulated during FSH-induced gran-
ulosa cell maturation [49]. This pattern suggests a role for
CTGF in follicular angiogenesis and during the rapid
growth of antral follicles. However, studies on CTGF
receptor have yet to be described and its role in the follic-
ular angiogenesis has yet to be established. The specific
localisation of CTGF mRNA in endothelial cells and
fibroblasts in the corpus luteum further supports a role
ovarian angiogenesis [14,50].
Thrombospondins
Thrombospondins -1 and -2 are large glycoproteins found
in the extracellular matrix and act as autocrine factors.
Included in the action of thrombospondins are anti-ang-
iogenic and anti-cell migration properties. They are often
produced at a rate inversely proportional to that of VEGF
and counteract pro-angiogenic stimuli. Thrombospondin
localisation in the ovary has been investigated in the rat
[51] and cow [52]. Thrombospondin-1 and its cell surface
receptor CD36, are localised in highest amounts in the
granulosa cells of small developing follicles in the cow;
expression then declines such that it is absent from large
follicles [52]. Thrombospondin mRNA and protein in the
granulosa lysates and follicular fluid concentrations
decline as the follicle develops, which is something simi-
lar to CTGF [52]. This pattern of synthesis indicates that
thrombospondins are involved in suppressing the devel-
opment of blood vessels during the early stages of devel-
opment, helping to restrict follicle growth until a
synchronized series of events involving the synthesis of
VEGF and its receptors is set in motion. In the bovine fol-
licle, thrombospondin production in granulosa cell is
stimulated by FSH, while LH has no effect [52].
Discovery of other candidates for follicular angiogenesis by 
microarrays
Another way of gaining information on the role of follic-
ular fluid and granulosa cells in the regulation of endothe-
lial cell gene expression has been to use microarray
technology to compare gene expression between unstim-
ulated human umbilical vein endothelial cells treated
with either human follicular fluid or culture medium con-
ditioned by human granulosa cells [53]. On the basis of
comparing the relative pro-and anti- angiogenic potential,
it was concluded that follicular fluid was predominantly
anti-angiogenic and it may provide a molecular shield
that prevents premature vascularisation of the pre-ovula-
tory follicle. Thus, down regulation of pro-angiogenic
genes, fibulin-5 and elastin and up regulation of Ang-2
and gro-beta (CXCL2) were observed. There is little infor-
mation on the chemokine gro-beta in the ovary, but in
other systems it enhances monocyte adhesion to endothe-
lial cells and inhibits growth-factor stimulated prolifera-
tion.Reproductive Biology and Endocrinology 2006, 4:18 http://www.rbej.com/content/4/1/18
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Conclusion
Angiogenesis plays a critical role in follicular develop-
ment. The vasculature proliferates and regresses through-
out the lifespan of the follicle, but its importance in
governing follicle selection on one hand and the early
onset of atresia have yet to be established. Many potential
candidates involved in the regulation of angiogenesis, vas-
cular permeability and maturation of the vasculature are
present in the follicle. For some of these factors, such as
VEGF, their functional role can be established by inhibit-
ing their action in vivo. The approach described in this
review of identifying potential candidate molecules and
inhibiting their action in vivo using specific antagonists to
determine effects on follicular angiogenesis, development
and function should provide a powerful tool to elucidate
their physiological role and identify ways of either
increasing or decreasing ovarian angiogenesis in the
clinic.
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